Skip to main content
Molecular Vision logoLink to Molecular Vision
. 2012 Aug 7;18:2190–2194.

PAX6 analysis of two sporadic patients from southern China with classic aniridia

Ying Lin 1,2, Xialin Liu 1, Shanshan Yu 1, Lixia Luo 1, Xuanwei Liang 1, Zhonghao Wang 1, Chuan Chen 1, Yi Zhu 1, Shaobi Ye 1, Hong Yan 1, Yizhi Liu 1,
PMCID: PMC3425573  PMID: 22919266

Abstract

Purpose

To investigate the paired box 6 (PAX6) gene in two sporadic patients from southern China presenting with classic aniridia.

Methods

The two sporadic patients underwent complete physical and ophthalmic examinations. Genomic DNA was extracted from the leukocytes of the peripheral blood collected from the families of the two sporadic patients and 100 unrelated control subjects from the same population. Exons 4–13 of PAX6 were amplified by polymerase chain reaction (PCR) and sequenced directly. The ophthalmic examinations included best-corrected visual acuity, slit-lamp examination, fundus examination, optical coherence tomography, and Pentacam and Goldmann perimetry.

Results

The two patients were affected with aniridia accompanied by nystagmus. A heterozygous PAX6 frameshift mutation in exon 7, c.375_376delAG (p.Arg125SerfsX7), was identified in sporadic patient 1 and not in any of the unaffected family members and normal controls. One novel mutation in exon 10, c.868_871dupAGTT (p.Phe291X), was detected in sporadic patient 2. The frameshift mutation we identified has not previously been reported either in China or abroad.

Conclusions

Although PAX6 mutations and polymorphisms have been reported in various ethnic groups, we report, for the first time, the identification of one new PAX6 mutation in Chinese aniridia patient.

Introduction

Congenital aniridia is a rare ocular disease usually caused by mutations in the paired box 6 (PAX6) gene, which is located on chromosome 11p13 [1-4]. The disease is characterized by the partial or complete absence of the iris, and is accompanied by other symptoms, including corneal degeneration, cataract, foveal and optic nerve hypoplasia, and nystagmus [5-13]. Two-thirds of aniridia cases are inherited in an autosomal, dominant fashion with variable expressivity, and the other cases are sporadic.

A large number of sporadic cases suggest the diversity of PAX6 mutations. At present, the PAX6 mutation database lists more than 500 different mutations of the PAX6 gene.

This study analyzes the coding sequences of PAX6 in two sporadic patients with aniridia. One novel PAX6 mutation was detected in the Chinese population; both mutations were heterozygous.

Methods

The aniridia family

Two sporadic patients were diagnosed with aniridia at the Zhongshan Ophthalmic Center.

We performed the ophthalmic examinations as follows:

  • Visual acuity was examined using the ETDRS chart (Precision Vision; La Salle, IL).

  • An anterior segment photograph was obtained using a BX 900 Slit-Lamp (Haag-Streit; Bern, Switzerland).

  • A fundus photograph was obtained using a Heidelberg Retina Angiograph (Heidelberg Engineering; Heidelberg, Germany).

  • Optical coherence tomography (OCT) scans (TOPCON; Tokyo, Japan) were used to assess the thickness and pathology of the posterior pole of the retina.

  • Anterior segment dimensions were measured with a Pentacam (HR version 70700; Oculus; Weltzar, Germany).

In addition, we performed complete physical examinations of the patients to exclude systemic diseases.

Sample collection

The two sporadic patients were identified at the Zhongshan Ophthalmic Center. The parents, the brothers and sisters of the two patients, and 100 subjects (25.34±8.63 years old, 45 male) from the same population without diagnostic features of aniridia, were recruited to serve as normal controls. After obtaining informed consent from all participating individuals according to the principles of the Declaration of Helsinki, the peripheral venous blood samples were collected for genomic DNA extraction from the blood leucocytes via standard protocol and procedures.

Detection of the mutation

All coding exons of the known candidate gene (PAX6), as well as their flanking regions, were amplified by PCR with primers [14] (Table 1). The sequencing results were analyzed using Chromas (version 2.3; Technelysium Pty Ltd.; Brisbane, QLD, Australia) and compared with the reference sequences in the database at the National Center for Biotechnology Information (NCBI; NC_000011.9). The superimposed mutant PCR products were sub-cloned into pGEM-T vector (Promega, Madison, WI) and sequenced to identify the mutation.

Table 1. Primers used for PCR.

Exon Forward (5′-3′) Reverse (5′-3′) Product size (bp) Annealing temperature (°C)
4
TGCAGCTGCCCGAGGATTA
GCACCCCGAGCCCGAAGTC
144
66
5
TCCCTCTTCTTCCTCTTCACT
GGGGTCCATAATTAGCATC
301
58
5 a,6
GCTCTCTACAGTAAGTTCTC
AGGAGAGAGCATTGGGCTTA
457
59
7
AATCCACCCACTGTCCCG
CCAGCCACCTTCATACCG
542
60
8
TCAGGTAACTAACATCGCA
GTTGACTGTACTTGGAAGAA
719
53
9,10,11
GAGGTGGGAACCAGTTTGATG
CAAGCCAATCTCTGTAGTGCG
890
52
12
GCTGTGTGATGTGTTCCTCA
AAGAGAGATCGCCTCTGTG
245
58
13 CATGTCTGTTTCTCAAAGGG CCATAGTCACTGACTGAATTAACAC 202 58

Summary of the primers and products length used for the amplification of the exons of PAX6.

Results

Clinical data

The two sporadic patients (case 1 and case 2) studied in this report originated from the southern area of China. Both of them had aniridia and nystagmus without other systemic diseases.

The right eye of patient 1 (25 years old, male) had very serious cataracts and corneal degeneration (Figure 1A); so, we could not perform all of the examinations; applanation tonometry revealed normal intraocular pressure in both eyes. The widths of the corneas of patient 1 were 10.5 mm (OD) and 10.5 mm (OS), respectively. The axial length of the left eye was 26.02 mm. The lens of the left eye had partial opacities (Figure 1B and Figure 2A). We could not examine the fundus of the right eye due to the cataracts and corneal degeneration. No abnormalities were detected in the retina, choroids, and optic nerve of the left eye. The anterior segment photograph, taken with a Pentacam, is shown in Figure 2A; the anterior chamber depth was 1.93 mm (OS). When this study was performed, the patients could detect only light perception (OD) and hand movement (OS).

Figure 1.

Figure 1

Anterior segment photographs of case 1 and case 2 patients with aniridia are shown. A: Shows the case 1 patient (25 years old, male), who had very serious cataracts and corneal degeneration, in addition to aniridia of the right eye. B: Shows the left eye of patient 1, who had partial cataracts. C and D: Show anterior segment photographs of both eyes of case 2. Some pigment particles precipitated in the front of the anterior lens capsule.

Figure 2.

Figure 2

Pentacam photographs of the two patients. A: A Pentacam photo shows the anterior segment picture of the left eye of case 1 (with partial cataracts). B: A Pentacam photo shows the anterior segment picture of the left eye of case 2.

The visual acuity of the case 2 patient (8 years old, female), as measured by logarithm of the minimum angle of resolution (Log MAR), was 2.0 (OD) and 2.0 (OS). The widths of the corneas of the case 2 patient were 10.5 mm (OD) and 10.5 mm (OS), respectively. The axial lengths of the eyeballs were 22.45 mm (OD) and 22.59 mm (OS), respectively. Figure 1C,D shows anterior segment photographs of both eyes of the case 2 patient. Some pigment particles precipitated in the front of the anterior lens capsule. No abnormalities were detected in the retina, choroids, and optic nerve. The anterior segment photograph of the left eye, taken with a Pentacam, is shown in Figure 2B. The anterior chamber depths were 2.42 mm (OD) and 2.28 mm (OS), respectively.

Mutation screening

In sporadic patient 1, a heterozygous AG deletion at nucleotide 375–376 (c.375_376delAG), in exon 7 of the PAX6 gene, was confirmed by sequencing (Figure 3). This frameshift mutation is predicted to cause a premature termination codon (PTC) 7 codons downstream from the first new inappropriate codon 125 created by the nucleotide mutation (p.Arg125SerfsX7).

Figure 3.

Figure 3

The DNA sequence of a part of the PAX6 gene in the affected patients and unaffected individuals is shown. Case 1 represents a heterozygous AG deletion at nucleotide 375–376 (c.375_376delAG) in exon 7 of the PAX6 gene. This frameshift mutation was predicted to cause a PTC seven codons downstream from the first new inappropriate codon 125 created by the nucleotide mutation (p.Arg125SerfsX7). The underlining (“Wild” graph) shows the AG in the normal controls, which the affected patients lacked (the arrow pointing to in the “Mutant and Heterozygous” graph). Case 2 represents one novel mutation in exon 10, c.868_871dupAGTT (p.Phe291X); a 4-nucleotide (AGTT) duplication generated a frameshift mutation in exon 10, and this frameshift mutation was predicted to cause a PTC in the codon 291 created by the nucleotide duplication.

One novel mutation in exon 10, c.868_871dupAGTT (p.Phe291X), was detected in sporadic patient 2 (Figure 3); 4-nucleotide (AGTT) duplication generated a frameshift mutation in exon 10, and this frameshift mutation was predicted to cause a PTC in the codon 291 created by the nucleotide duplication. The frameshift mutation we identified has not previously been reported either in China or abroad. No mutations were found in any of the unaffected family members and the normal controls.

Discussion

In this study, we found two mutations—one in each of the two exons of the PAX6 gene—that are associated with aniridia: c.375_376delAG and c.868_871dupAGTT. These two mutations, rather than being rare polymorphisms in the normal population, were the causative mutations in the two sporadic patients.

The characteristic of the c.375_376delAG mutation, which was identified in exon 7 of PAX6 of the family members, is that it occurred at a hotspot for mutations that had already been shown among other ethnic groups in the PAX6 Allelic Variant Database.

One novel mutation in exon 10, c.868_871dupAGTT (p.Phe291X), generated a frameshift mutation in exon 10, and this frameshift mutation was predicted to cause a PTC in the codon 291 created by the nucleotide duplication. The frameshift mutation we identified has not previously been reported either in China or abroad.

We reviewed the mutations archived in the PAX6 Allelic Variant Database. We found that over three-quarters of aniridia cases are caused by mutations that introduce a PTC into the open reading frame of PAX6, just as our study has demonstrated.

To avoid the potentially lethal consequences of producing truncated polypeptides that could interfere with cell functions, mRNAs carrying premature termination codons were rapidly degraded in vivo by a form of RNA surveillance known as nonsense-mediated mRNA decay (NMD) [15,16].

The presence of cataracts was the most common disorder associated with the aniridic patients, and it increased with age [17-20]. So, patient 1 (25 years old) had more serious cataracts than patient 2 (8 years old). There was a relatively high risk of intraoperative and postoperative complications in these aniridic cataract patients. They exhibited fragile anterior lens capsules, as well as either associated lens subluxation or weak zonules. Therefore, preventing the progress of cataracts is of vital importance for patients with aniridia.

In summary, this study identified one novel mutation of PAX6 in one Chinese sporadic patient with aniridia. This finding expands the mutation spectrum of PAX6. In families where aniridia is present, the results of the study are useful and valuable for genetic counseling and prenatal diagnosis that is accompanied by corneal degeneration, eyeball horizontal tremors, and cataracts.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grant No.30973277); the Science and Technology Planning Project of Guangdong Province, China (Grant No. 2010B090400416); the Key Clinical Program of the Ministry of Health (Grant No. 2010. 439); and the Youth Project of Fundamental Research Funds of the State Key Laboratory of Ophthalmology. Professors Hong Yan and Yizhi Liu contributed equally to the research project, and thus, can both be considered as co-corresponding authors.

References

  • 1.Davis A, Cowell JK. Mutations in the PAX6 gene in patients with hereditary aniridia. Hum Mol Genet. 1993;2:2093–7. doi: 10.1093/hmg/2.12.2093. [DOI] [PubMed] [Google Scholar]
  • 2.Hingorani M, Moore A. Aniridia. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 2003 [Google Scholar]
  • 3.Hanson IM, Seawright A, Hardman K, Hodgson S, Zaletayev D, Fekete G, van Heyningen V. PAX6 mutations in aniridia. Hum Mol Genet. 1993;2:915–20. doi: 10.1093/hmg/2.7.915. [DOI] [PubMed] [Google Scholar]
  • 4.Glaser T, Walton DS, Maas RL. Genomic structure, evolutionary conservation and aniridia mutations in the human PAX6 gene. Nat Genet. 1992;2:232–9. doi: 10.1038/ng1192-232. [DOI] [PubMed] [Google Scholar]
  • 5.Dansault A, David G, Schwartz C, Jaliffa C, Vieira V, de la Houssaye G, Bigot K, Catin F, Tattu L, Chopin C, Halimi P, Roche O, Van Regemorter N, Munier F, Schorderet D, Dufier JL, Marsac C, Ricquier D, Menasche M, Penfornis A, Abitbol M. Three new PAX6 mutations including one causing an unusual ophthalmic phenotype associated with neurodevelopmental abnormalities. Mol Vis. 2007;13:511–23. [PMC free article] [PubMed] [Google Scholar]
  • 6.Neethirajan G, Solomon A, Krishnadas SR, Vijayalakshmi P, Sundaresan P. Genotype/phenotype association in Indian congenital aniridia. Indian J Pediatr. 2009;76:513–7. doi: 10.1007/s12098-009-0075-4. [DOI] [PubMed] [Google Scholar]
  • 7.Lee H, Khan R, O'Keefe M. Aniridia: current pathology and management. Acta Ophthalmol. 2008;86:708–15. doi: 10.1111/j.1755-3768.2008.01427.x. [DOI] [PubMed] [Google Scholar]
  • 8.Edén U, Iggman D, Riise R, Tornqvist K. Epidemiology of aniridia in Sweden and Norway. Acta Ophthalmol. 2008;86:727–9. doi: 10.1111/j.1755-3768.2008.01309.x. [DOI] [PubMed] [Google Scholar]
  • 9.Traboulsi EI, Ellison J, Sears J, Maumenee IH, Avallone J, Mohney BG. Aniridia with preserved visual function: a report of four cases with no mutations in PAX6. Am J Ophthalmol. 2008;145:760–4. doi: 10.1016/j.ajo.2007.12.012. [DOI] [PubMed] [Google Scholar]
  • 10.Mahale A, Poornima V, Shrestha M. WAGR syndrome–a case report. Nepal Med Coll J. 2007;9:138–40. [PubMed] [Google Scholar]
  • 11.Sisodiya SM, Free SL, Williamson KA, Mitchell TN, Willis C, Stevens JM, Kendall BE, Shorvon SD, Hanson IM, Moore AT, van Heyningen V. PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans. Nat Genet. 2001;28:214–6. doi: 10.1038/90042. [DOI] [PubMed] [Google Scholar]
  • 12.Ticho BH, Hilchie-Schmidt C, Egel RT, Traboulsi EI, Howarth RJ, Robinson D. Ocular findings in Gillespie-like syndrome: association with a new PAX6 mutation. Ophthalmic Genet. 2006;27:145–9. doi: 10.1080/13816810600976897. [DOI] [PubMed] [Google Scholar]
  • 13.Xiao X, Li S, Zhang Q. Microphthalmia, late onset keratitis, and iris coloboma/aniridia in a family with a novel PAX6 mutation. Ophthalmic Genet. 2011 doi: 10.3109/13816810.2011.642452. [DOI] [PubMed] [Google Scholar]
  • 14.Lin Y, Liu X, Liang X, Li B, Jiang S, Ye S, Yang H, Lou B, Liu Y. PAX6 analysis of one family and one sporadic patient from southern China with classic aniridia. Mol Vis. 2011;17:3116–20. [PMC free article] [PubMed] [Google Scholar]
  • 15.Ramirez-Miranda A, Zenteno JC. PAX6 gene intragenic deletions in Mexican patients with congenital aniridia. Mol Vis. 2006;12:318–23. [PubMed] [Google Scholar]
  • 16.Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay. Cell. 1999;96:307–10. doi: 10.1016/s0092-8674(00)80542-5. [DOI] [PubMed] [Google Scholar]
  • 17.Grønskov K, Rosenberg T, Sand A, Brondum-Nielsen K. Mutational analysis of PAX6: 16 novel mutations including 5 missense mutations with a mild aniridia phenotype. Eur J Hum Genet. 1999;7:274–86. doi: 10.1038/sj.ejhg.5200308. [DOI] [PubMed] [Google Scholar]
  • 18.Gupta SK, De Becker I, Tremblay F, Guernsey DL, Neumann PE. Genotype/phenotype correlations in aniridia. Am J Ophthalmol. 1998;126:203–10. doi: 10.1016/s0002-9394(98)00191-3. [DOI] [PubMed] [Google Scholar]
  • 19.Glaser T, Jepeal L, Edwards JG, Young SR, Favor J, Maas RL. PAX6 gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and central nervous system defects. Nat Genet. 1994;7:463–71. doi: 10.1038/ng0894-463. [DOI] [PubMed] [Google Scholar]
  • 20.Park SH, Park YG, Lee MY, Kim MS. Clinical features of Korean patients with congenital aniridia. Korean J Ophthalmol. 2010;24:291–6. doi: 10.3341/kjo.2010.24.5.291. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Molecular Vision are provided here courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China

RESOURCES